Biosensors Lunch Symposium
|
|
- Katrina Powell
- 6 years ago
- Views:
Transcription
1 Are Current DES the Final Answer? BioFreedom TM : the Polymer-Free Biolimus A9TM Coated Stent Biosensors Lunch Symposium 25 th April 2013 Prof. Stephen WL Lee, JP 李偉聯 MD FRCP(Lon. Edin. Glas.) FHKCP FHKAM FACC FSCAI Chief of Cardiology, Professor & Senior Consultant Department of Medicine, Queen mary Hospital, University of Hong Kong
2 Potential conflicts of interest Speaker s name: Stephen Wai-luen LEE (Queen Mary Hospital, University of Hong Kong) I have the following potential conflicts of interest to report: x Research contracts Consulting Employment in industry Stockholder of a healthcare company Owner of a healthcare company Other(s) I do not have any potential conflict of interest to declare The stents were provided by Biosensors as investigational devices. The Core Laboratory Charges are supported by Biosensors.
3 All current DES = can achieved neointimal suppression PCI objective = purely for achieving revascularization = without complicated issues of But many DES still show Poor Stent Healing :- drug cytotoxicity, polymer hypersensitivity, local inflammatory reactions, loss endothelial and vasomotor functions Acute failure Restenosis Stent thrombosis Prolonged DAPT Bleeding Stent thrombosis MACE
4 Most powerful histological predictor of stent thrombosis = endothelial coverage Most powerful surrogate indicator of endothelialization = neointimal coverage Best morphometric predictor of LST = ratio of uncovered to total stent struts Finn et al. Circulation 2007;115; Is stent thrombosis genuine?
5 Myocardial Infarction (%) Target-Lesion Revascularization (%) Stent Thrombosis (%) Death (%) Pooled Analysis of Data Comparing SES With BMS Estimated 4-year cumulative incidence of stent thrombosis, death, MI, and TLR Sirolimus stent (1.2%) P=.20 Bare-metal stent (0.6%) Years Since Procedure 8 6 Sirolimus stent (6.7%) 4 P=.23 2 Bare-metal stent (5.3%) Years Since Procedure Bare-metal stent (6.2%) Sirolimus stent (6.4%) P= Years Since Procedure Bare-metal stent (23.6%) P<.001 Sirolimus stent (7.8%) Years Since Procedure Stone et al. N Engl J Med. 2007;356:
6 Myocardial Infarction (%) Target-Lesion Revascularization (%) Stent Thrombosis (%) Death (%) Pooled Analysis of Data Comparing PES With BMS Estimated 4-year cumulative incidence of stent thrombosis, death, MI, and target lesion revasc Paclitaxel stent (1.3%) Bare-metal stent (0.9%) P= Years Since Procedure Bare-metal stent (6.6%) 2 0 Paclitaxel stent (6.1%) P= Years Since Procedure Paclitaxel stent (7.0%) Bare-metal stent (6.3%) 2 P= Years Since Procedure Bare-metal stent (20.0%) P<.001 Paclitaxel stent (10.1%) Years Since Procedure Stone et al. N Engl J Med. 2007;356:
7 RESOLUTE All Comers Simple Patients Clinical Outcomes to 12 Months R-ZES (n=376) EES (n=396) P=0.79 P=0.50 P=0.70 P=0.48 P=0.12 P=0.49 % Death Cardiac Death TV-MI Cardiac death or TV-MI ARC ST Def/Prob CI-TLR Stefanini et al., JACC 2011
8 RESOLUTE All Comers Complex Patients Clinical Outcomes to 12 Months R-ZES (n=764) EES (n=756) P=0.02 P=0.24 P=0.90 P=0.58 P=0.26 P=0.80 % Death Cardiac Death TV-MI Cardiac death or TV-MI ARC ST Def/Prob CI-TLR Resolute-US Trial: Stefanini et al., JACC similar 2011 results between the 2 stents
9 Biolimus-A9 Eluting Stent Biolimus is a semi-synthetic sirolimus analogue with 10x higher lipophilicity and similar potency as sirolimus. Biolimus is immersed at a concentration of 15.6 g/mm into a biodegradable polymer, polylactic acid, and applied solely to the abluminal stent surface by a fully automated process. Biolimus is co-released with polylactic acid and completely desolves into carbon dioxide and water after a 6-9 months period. The stainless steel stent platform has a strut thickness of 120 m with a quadrature link design.
10 LEADERS All-comers Trial Clinically-Indicated TVR * p-value for superiority Serruys et al., oral abstract presentation, TCT 2012
11 Patient Oriented Endpoints (Death, MI, TLR, TVR) LEADERS All-comers Trial Biomatrix (n=850) versus Cypher (n=850). DAPT = 12 months. 81% off-label use. 1 o endpoint: MACE: Cardiac death, MI, clinically-indicated TVR (9 months) 5 years data available. Better outcomes than Cypher at 5 years.
12 LEADERS all-comers Trial Definite ST (ARC) Landmark 1 Year P for interaction=0.022 * p-value for superiority Serruys et al., oral abstract presentation, TCT 2012
13
14 ESC guidelines 2010 But these are guidelines based on clinical outcomes. Is there any more scientific approach:- (In-vivo assessment of stent healing guiding of DAPT duration) Wijns et al., Eur Heart J. 2010; 31(20):
15 Highest lipophilicity of the common limus drugs 1 1 Biomatrix (Biolimus-A9 PLA) DES Biofreedom (Biolimus-A9 ) DCS Polymer-free drug elution via porous surface Potential Advantages Reduced late adverse effects due to polymer hypersensitivity Improved surface integrity with no polymer to be sheared or peeled away from the stent struts Possible shorter DAPT with better healing without polymer and inner BMS surface
16 Components of BioFreedom DCS Metal / Design Strut Thickness ~ microns Polymer Durable Biodegradable Drug and Release kinetics determine Anti-proliferative effects Drugs Sirolimus-135 g Everolimus 100 g Paclitaxel- 80 g Biolimus A9 225 g
17 Pre-clinical efficacy evaluation BFD SD BFD LD Standard Dose BioFreedom Low Dose BioFreedom Sirolimus-eluting stents Bare metal stents Tada et al., Circ Cardiovasc Interv 2010;3;
18 BioFreedom FIM design First Cohort 4 Month Angio FU 75 patients BioFreedom FIM 182 patients 12 Month Clinical FU 99% Second Cohort 12 Month Angio FU 107 patients Angio FU 92% Angio FU 92% BioFreedom standard dose (BFD SD) N=25 BioFreedom low dose (BFD LD) N=26 TAXUS Liberté N=24 BioFreedom standard dose (BFD SD) N=35 BioFreedom low dose (BFD LD) N=36 TAXUS Liberté N=36 Enrollment Period Sept 2008 Jan 2009 Enrollment Period Jan 2009 Jun o End-point: In-stent Late Lumen Loss at 4 months (LD) and 12 months (Standard Dose)
19 Antiplatelet Agent Utilization All patients- 1 st and 2 nd Cohorts BFD SD BFD LD Taxus P value* Aspirin At 30 days 56/58 (97%) 61/62 (98%) 58/59 (98%) 0.55 At 4 months 56/58 (97%) 61/62 (98%) 56/57 (98%) 0.57 At 1 year 56/58 (97%) 60/61 (98%) 58/60 (97%) 0.97 At 2 years 52/58 (90%) 57/59 (97%) 53/59 (90%) 0.98 At 3 years 52/56 (93%) 54/57 (95%) 53/57 (93%) 0.98 Clopidrogel or ticlopidine At 30 days 57/58 (98%) 61/62 (98%) 59/59 (100%) 0.31 At 4 months 57/58 (98%) 61/62 (98%) 57/57 (100%) 0.32 At 1 year 48/58 (83%) 41/61 (67%) 47/60 (78%) 0.54 At 2 years 4/58 (6.9%) 7/59 (12%) 13/59 (22%) At 3 years 7/56 (13%) 7/57 (12%) 7/57 (12%) 0.97 Dual antiplatelet therapy At 30 days 56/58 (97%) 61/62 (98%) 58/59 (98%) 0.55 At 4 months 56/58 (97%) 61/62 (98%) 56/57 (98%) 0.57 At 1 year 47/58 (81%) 40/61 (66%) 45/60 (75%) 0.43 At 2 years 3/58 (5.2%) 7/59 (12%) 11/59 (19%) At 3 years 7/56 (13%) 6/57 (11%) 5/57 (8.8%) 0.52 * P-values compare BFSD vs TAXUS Grube E., oral presentation, TCT 2012
20 (mm) In-stent Late Lumen Loss (12 months) 2 nd Cohort PRIMARY ENDPOINT 0.5 P = 0.001* (p=0.11**) 0.4 P = 0.21* (p=0.55**) 0.35 [0.22, 0.57] [0.09, 0.39] 0.22 [0.17, 0.66] BFD SD BFD LD TAXUS N = 31 N = 35 N = 31 *Non-inferiority tests based on the mean. **Superiority tests. All values are presented as median [IQR]. Grube E., oral presentation, TCT 2010
21 BioFreedom 12-Month Outcomes All patients 1 st and 2 nd Cohorts (98.9%) EVENT BFD SD N = 60 BFD LD N = 62 TAXUS N = 60 MACE (All Death, MI, Emergent Bypass or TLR) 3 (5.1%) 7 (11.5%) 3 (5.0%) All Death 1 (1.7%) 0 (0.0%) 0 (0.0%) MI 1 (1.7%) 1 (1.6%) 0 (0.0%) Q Wave MI 0 (0.0%) 0 (0.0%) 0 (0.0%) Non-Q Wave MI 1 (1.7%) 1 (1.6%) 0 (0.0%) Emergent Bypass 0 (0.0%) 0 (0.0%) 0 (0.0%) TLR 1 (1.7%) 6 (9.8%) 3 (5.0%) Definite/probable stent thrombosis (ARC) 0 (0.0%) 0 (0.0%) 0 (0.0%) All P values are non-significant. Tests were performed for BFD SD vs. TAXUS and BFD LD vs. TAXUS. Grube E., oral presentation, TCT 2010
22 BioFreedom 36-Month Outcomes All patients 1 st and 2 nd Cohorts (96.1%) EVENT MACE (All Death, MI, Emergent Bypass or TLR) BFD SD N = 60 BFD LD N = 62 TAXUS N = 60 7(11.9%) 11(18.1%) 6(10.0%) All Death 3(5.1%) 2(3.3%) 1(1.7%) MI 1(1.7%) 2(3.4%) 1(1.7%) Q Wave MI 0(0.0%) 0(0.0%) 0(0.0%) Non-Q Wave MI 1(1.7%) 2(3.4%) 1(1.7%) Emergent Bypass 0(0.0%) 0(0.0%) 0(0.0%) TLR 3(5.2%) 8(13.2%) 4(6.7%) Definite/probable stent thrombosis (ARC) 0(0.0%) 0(0.0%) 0(0.0%) All P values are non-significant. Tests were performed for BFD SD vs. TAXUS and BFD LD vs. TAXUS Grube E, TCT 2012
23 BioFreedom FIM Conclusions A polymer free BA9 stent. Non-inferiority (with trend towards superiority) in the primary endpoint (in-stent LLL 12M) vs. Taxus (P=0.001 for non-inferiority; P=0.11 for superiority) Similar rates of MACE and TLR up to 3 years vs. Taxus Liberté. Sustained safety up to 3 years, including absence of definite/probable stent thrombosis. Could be promising better healing (no polymer hypersensitivity). May reduce DAPT duration. Less late stent thrombosis.
24 Leaders Free Trial Randomise, double-blind, 1:1 control study. 60+ centres world-wide patients with high risk of bleeding. FU for 2 years. Two stents Biosensors BioFreedom BA9 Drug-Coated Coronary Stent (DCS) Biosensors Gazelle Bare Metal Coronary Stent (BMS) One DAPT regimen ASA mg OD, indefinitely 1 month DAPT (Clopidogrel 75 mg OD or another P2Y12 inhibitor) Co-Primary Endpoints (1) Safety (non-inferiority) MACE (Death, MI, Stent Thrombosis) (2) Efficacy (superiority) - clinically-driven TLR
25 Participating Centers Canada Brazil Austria Belgium Denmark France Germany Israel Italy Latvia Netherlands Norway Spain Switzerland Poland UK Hong Kong Malaysia Singapore Thailand Australia Argentina Principal Investigators: P. Urban (Switzerland) A. Abizaid (Brazil) I. Meredith (Australia)
26 EGO-BioFreedom Study Real World, All Comers With symptomatic coronary artery disease N = 100 patients Single Center BioFreedom DCS Stent Initial PCI procedure angiogram (baseline OCT) Randomly assigned to 6 FU groups at 1,2,3,4,5 & 6 months (OCT) Final restudy angiogram & OCT at 9 months OCT Clinical Endpoint Baseline 1mo 2mo 3mo 4mo 5mo 6mo 9 mo 12mo 24mo 1 st Angiographic & OCT FU 2 nd OCT FU Primary Endpoint: OCT % strut coverage from 1 to 6 months. Secondary Endpoints: Clinical Endpoints (MACE) QCA & OCT Findings at 9 months Drug therapy: ASA and clopidogrel (per guidelines for 9 months) Clinical Follow up: 30d, 6mo, 9mo, 12mo, 1yr, 2yr.
27 The EGO-BioFreedom Study EGO-BioFreedom Study Stringent Classification of Early Strut Coverage
28 1 Month FU 2 Month FU
29
30 Sequential longitudinal OCT FU with a very stringent strut coverage classification OCT should be adopted as a vigorous & novel step for guiding any new stent platform. Baseline OCT 5 groups (1 to 5 months) OCT strut coverage 9 months OCT (late loss NIH) Proper stent apposition Degree of early coverage (healing profile) Guiding appropriate DAPT duration Little late loss as a DES Reduced stent thrombosis A B C No Stent Thrombosis D E F Minimal late catch-up Very stringent strut coverage classification May predict / prevent late stent thrombosis, rather than waiting for years to observe for adverse effects. BioFreedom Stent : could be a Novel Device?!!
31 The Leaders-Free & EGO-Biofreedom Study Thank you
32 BMS vs. DES All current DES = can achieved neointimal suppression PCI objective = purely for achieving revascularization = without complicated issues of But many DES still show poor Stent Healing = drug cytotoxicity, polymer hypersensitivity, local inflammatory reactions, loss endothelial and vasomotor functions Acute failure Restenosis Stent thrombosis Prolonged DAPT Stent thrombosis MACE
Taking DES technology from concept to long term clinical evidence. Aurore Bouvier Global Product Manager Biosensors Europe
Taking DES technology from concept to long term clinical evidence Aurore Bouvier Global Product Manager Biosensors Europe My conflicts of interest are: Full time employee of Biosensors Europe SA BA9 shows
More informationEvaluation COMBO s Healing Profile The EGO-COMBO Serial OCT Study
Evaluation COMBO s Healing Profile The EGO-COMBO Serial OCT Study OrbusNeich Dual Therapy COMBO Stent Symposium 25 th April 2013 Prof. Stephen WL Lee, JP 李偉聯 MD FRCP(Lon. Edin. Glas.) FHKCP FHKAM FACC
More informationMoins de 6 mois d antiagrégants après DES?
Moins de 6 mois d antiagrégants après DES? High Tech - Marseille 25 au 27 janvier 2011 Marie-Claude MORICE, MD, FESC, FACC Massy, France Pas de conflit d interet Was optimal duration of DAPT already established
More informationBIOFREEDOM: Polymer free Biolimus A9 eluting
TCTAP 2011 Seoul, April 27 29, 2011 BIOFREEDOM: Polymer free Biolimus A9 eluting Stents and Paclitaxel eluting stents Eberhard Grube MD, FACC, FSCAI Hospital Oswaldo Cruz - Dante Pazzanese, São Paulo,
More informationBiolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer: A Randomised, Non-Inferiority Trial
Limus Eluted From A Durable vs ERodable Stent Coating Biolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer: A Randomised, Non-Inferiority Trial Stephan
More informationDUREE de la BITHERAPIE dans les ETUDES LEADERS. J BERLAND Clinique Saint Hilaire ROUEN
DUREE de la BITHERAPIE dans les ETUDES LEADERS J BERLAND Clinique Saint Hilaire ROUEN LEADERS all-comers Trial Design Stable and ACS Patients Undergoing PCI Assessor-blind 1:1 Randomisation N=1700 Patients
More informationDrug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
More informationFreedom to Treat Your High Bleeding Risk Patients. Tim Kinnaird University Hospital of Wales, Cardiff, UK
Freedom to Treat Your High Bleeding Risk Patients Tim Kinnaird University Hospital of Wales, Cardiff, UK Relevant Disclosures Honoraria for lectures from: o Eli Lilly & Co, Daiichi Sankyo, Boehringer,
More informationHCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?
HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic
More informationNobori Clinical Studies Up-dates. Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy
Nobori Clinical Studies Up-dates Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy Drug Eluting Stents High benefit in preventing restenosis and improving quality of life
More informationFrom a DES to a BMS* Biosensors Clinical Trial Program. Taking the LEAD in DES Clinical Excellence. From Single de Novo.
Biosensors Clinical Trial Program Taking the LEAD in DES Clinical Excellence Our trials gather clinical data for this technology from a wide range of patients, including those with single de novo lesions,
More informationTailored bifurcation therapy
Tailored bifurcation therapy Dedicated self-expanding platform that conforms to the specific bifurcation anatomy Full bifurcation lesion coverage without creating a false carina Bifurcation DES technology
More informationTwo-Year Outcomes of High Bleeding Risk Patients after Polymer-Free Drug-Coated Stents
Two-Year Outcomes of High Bleeding Risk Patients after Polymer-Free Drug-Coated Stents Philip Urban, Philippe Garot, Damras Tresukosol, Stuart J. Pocock, Ian Meredith, Alex Abizaid, Didier Carrié, Christoph
More informationBiolimus A9 Drug-Eluting Stents: Technical Aspects and a Comprehensive Review of the EU, Asia-Pacific, and US Clinical Trial Program
TCT Asia 2006 Biolimus A9 Drug-Eluting Stents: Technical Aspects and a Comprehensive Review of the EU, Asia-Pacific, and US Clinical Trial Program Eberhard Grube MD FACC, FSCAI HELIS Heart Center Siegburg,
More informationResolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program Prof. Ran Kornowski, MD, FESC, FACC Director - Division of Interventional Cardiology Rabin Medical Center and Tel Aviv University,
More informationSKG Congress, 2015 EVOLVE II. Stephan Windecker
SKG Congress, 2015 EVOLVE II Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland BIODEGRADABLE POLYMER DES Stefanini,
More informationStephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank
From ABSORB Cohort A to ABSORB III and IV Randomized Trials Stephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank Disclosures Consultant, Abbott Vascular
More informationChristian Spaulding. for the TYPHOON Investigators
Four-Year Follow-Up of the TYPHOON Study, a Multicenter, Randomized, Single-blind Trial To Assess The Use of the CYPHER Sirolimus-eluting Stent (SES) in Acute Myocardial Infarction Patients Treated With
More informationPolymer-Free Stent CX - ISAR
Polymer-Free Stent CX - ISAR Moo Hyun Kim, MD, FACC on behalf of Dr. Florian Krackhardt, Germany CX ISAR Stent : Features Intracoronary Stenting and Angiographic Results Strut Thickness of only 50/60 μm
More informationOCT Technology: Differences between Biodegradable and Durable Polymers: Insights from the LEADERS Trial LEADERS OCT
OCT Technology: Differences between Biodegradable and Durable Polymers: Insights from the LEADERS Trial LEADERS OCT Substudy Carlo Di Mario, MD Peter Barlis, MD Evelyn Regar, MD Peter Juni, MD Patrick
More informationInnovation in Cardiovascular Interventions. New DES, Scaffolds and other Devices Have Angioplasty Results Improved
Innovation in Cardiovascular Interventions New DES, Scaffolds and other Devices Have Angioplasty Results Improved Alexandra Lansky, MD Yale University School of Medicine University College of London DES
More informationBioabsorbable stents: early clinical results. Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals
Bioabsorbable stents: early clinical results Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals MY CONFLICTS OF INTEREST ARE: Clinical Events Committee member for
More informationEXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts
More informationDrug eluting stents From revolution to evolution. Current limitations
Drug eluting stents From revolution to evolution Current limitations Eric Eeckhout Centre Hospitalier Universitaire Vaudois Lausanne - Switzerland eric.eeckhout@chuv.ch Overview Historical perspective
More informatione-biomatrix PMS Registry A post market surveillance registry for the BioMatrix TM DES
e-biomatrix PMS Registry A post market surveillance registry for the BioMatrix TM DES Philip Urban La Tour Hospital, Geneva, Switzerland On behalf of the e-biomatrix PMS Registry Investigators: F. Eberli,
More informationPCI with Polymer-free Stent
PCI with Polymer-free Stent Florian Krackhardt, M.D. Department of Cardiology Charité Campus Virchow-Klinikum University Hospital Berlin, Germany Drug Eluting Stents: Present Coating Technology Solution
More informationBern-Rotterdam Cohort Study
Bern-Rotterdam Cohort Study Newer generation everolimus-eluting stents eliminate the risk of very late stent thrombosis compared with early generation sirolimus-eluting and paclitaxel-eluting stents Lorenz
More informationeluting Stents The SPIRIT Trials
Everolimus-eluting eluting Stents The SPIRIT Trials Gregg W. Stone, MD Columbia University Medical Center Cardiovascular Research Foundation Abbott XIENCE V Everolimus-eluting eluting Stent Everolimus
More informationThe tailored solution for your bifurcation therapy
The tailored solution for your bifurcation therapy The tailored solution for your bifurcation therapy Dedicated self-expanding platform that conforms to the specific bifurcation anatomy Full bifurcation
More informationEberhard Grube MD FSCAI, FACC
SCAI 30 th Annual Scientific Sessions Orlando/Fla BMS and DES Thrombosis Differences among DES Eberhard Grube MD FSCAI, FACC HELIOS Heart Center Siegburg, Siegburg, Germany Stanford University, School
More informationTNT Session. The latest clinical evidence in diabetics for the Amphilimus TM eluting polymer-free DES. Rafael Romaguera, MD
TNT Session The latest clinical evidence in diabetics for the Amphilimus TM eluting polymer-free DES Rafael Romaguera, MD Hospital de Bellvitge Barcelona Spain Disclosure Statement of Financial Interest
More informationCoronary Stent Choice in Patients With Diabetes Mellitus
Rome Cardiology Forum 2014 Coronary Stent Choice in Patients With Diabetes Mellitus Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University
More informationKomplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
More informationDisclosure Eberhard Grube, M.D.
Disclosure Eberhard Grube, M.D. I disclose the following financial relationships: Consultant Sadra Medical, Core Valve, Biosensors, Orbus Neich, Cordis Johnson & Johnson, Boston Scientific, Mitralign,
More informationNew Generation Drug- Eluting Stent in Korea
New Generation Drug- Eluting Stent in Korea Young-Hak Kim, MD, PhD Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose To briefly introduce the
More informationSecond Generation Drug Eluting Stents: From Inhibition to Healing
Second Generation Drug Eluting Stents: From Inhibition to Healing Mitchell W. Krucoff MD, FACC Professor of Medicine / Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke
More informationCatch-up Phenomenon: Insights from Pathology
Catch-up Phenomenon: Insights from Pathology Michael Joner, MD CVPath Institute Inc. Gaithersburg, MD USA Path Lessons learned from the BMS and DES (1 st Gen) era Neointimal Thickness [mm] In Stent Re
More informationSafety of Drug-Eluting Stents in Acute Coronary Syndromes
Rotterdam, June 11 th 2012 Safety of Drug-Eluting Stents in Acute Coronary Syndromes Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University
More informationOCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis?
OCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis? Juan F. Granada, MD Medical Director, Skirball Center for Cardiovascular Research
More informationDESolve NX Trial Clinical and Imaging Results
DESolve NX Trial Clinical and Imaging Results Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese, Sao Paulo, Brazil On behalf of the DESolve Nx Trial Investigators Please refer to the TCT2014 App or
More informationIan T. Meredith AM. MBBS, PhD, FRACP, FCSANZ, FACC, FSCAI, FAPSIC MonashHeart, Monash Medical Centre & Monash University Melbourne, Australia
Final five-year clinical outcomes in the EVOLVE trial: A randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent Ian T. Meredith AM MBBS, PhD, FRACP, FCSANZ, FACC, FSCAI,
More informationCOMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands
COMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands TCTAP 2010 Seoul, Korea Disclosures Research Foundation of the Cardiology Department has received unrestricted research grants from:
More informationElement Clinical Program Perseus Late Breaking News and the Platinum Study Design
Element Clinical Program Perseus Late Breaking News and the Platinum Study Design Ian T. Meredith MBBS, BSc(Hons), Ph.D, FRACP, FACC, FCSANZ, FSCAI, FAHA, FAPSIC Professor and Director of Monash HEART
More informationInspiron Stent. Clinical Research Program. Pedro A. Lemos MD PhD. Heart Institute InCor University of Sao Paulo Medical School Sao Paulo Brazil
Stent Clinical Research Program Pedro A. Lemos MD PhD Heart Institute InCor University of Sao Paulo Medical School Sao Paulo Brazil All faculty disclosures are available on the CRF Events App and online
More informationBioMatrix TM : The New Biodegradable Abluminally Coated DES BioMatrix TM Clinical Program
BioMatrix TM : The New Biodegradable Abluminally Coated DES BioMatrix TM Clinical Program T. Santoso Univ. of Indonesia Medical School Medistra Hospital Jakarta, Indonesia Biodegradable Abluminally Coated
More informationNEW GENERATION DES WITH NEW GENERATION POLYMERS. Prof. Dr. Rainer Wessely, Duisburg, Germany
NEW GENERATION DES WITH NEW GENERATION POLYMERS Prof. Dr. Rainer Wessely, Duisburg, Germany Sousa J et al., JACC Cardioasv Interv 2010 10 years DES NEXT DES BMS + DAPT DES DES + DAPT S A F E T Y BMS E
More informationReduction in Stent Thrombosis better tablets or better stents?
Reduction in Stent Thrombosis better tablets or better stents? Dr James Cotton MD FRCP Heart and Lung Centre Wolverhampton MY CONFLICTS OF INTEREST ARE Speaker Fees/Honoraria/Travel Support Lilly/Daiichi
More informationTHE ULTIMATE EVOLUTION IN DES TECHNOLOGY FOR DIABETICS: CRE8 EVO
The ultimate EVOlution in DES technology for diabetics: Cre8 EVO THE ULTIMATE EVOLUTION IN DES TECHNOLOGY FOR DIABETICS: CRE8 EVO Rafael Romaguera, MD Barcelona Spain Rafael Romaguera, MD Hospital de Bellvitge
More informationRun-Lin Gao, MD, FACC. On Behalf of I-LOVE-IT Trial Investigators
I-LOVE-IT A Prospective, Multicenter Clinical Trial of TIVOLI Bioabsorbable Polymer Based Sirolimus-Eluting vs. ENDEAVOR Zotarolimus- Eluting Stent in Patients with Coronary Artery Disease: 8-Month Angiographic
More informationBioresorbable polymer drug-eluting stents in PCI
EARN 3 FREE CPD POINTS CARDIOVASCULAR Leader in digital CPD for Southern African healthcare professionals The BIOFLOW-V trial, using the Orsiro ultrathin strut stent with biodegradable polymer, showed
More informationINDEX 1 INTRODUCTION DEVICE DESCRIPTION CLINICAL PROGRAM FIRST-IN-MAN CLINICAL INVESTIGATION OF THE AMAZONIA SIR STENT...
May 2017 INDEX 1 INTRODUCTION... 2 2 DEVICE DESCRIPTION... 3 ANTI-PROLIFERATIVE DRUG - SIROLIMUS... 3 BIODEGRADABLE POLYMERS... 3 SIROLIMUS CONTROLLED ELUTION... 4 STENT PLATFORM... 4 3 CLINICAL PROGRAM...
More informationCYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms. Campbell Rogers, M.D. Chief Technology Officer
Ground breaking, Life changing CYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms Campbell Rogers, M.D. Chief Technology Officer Disclosure Statement of Financial Interest I am a full-time
More informationDES in Diabetic Patients
DES in Diabetic Patients Charles Chan, M.D., FACC Gleneagles Hospital Singapore TCT ASIA PACIFIC 2007 Why do diabetics have worse outcome after PCI? More extensive atherosclerosis and diffuse disease Increase
More informationNon stent based intracoronary drug delivery
Non stent based intracoronary drug delivery Dariusz Dudek Department of Interventional Cardiology Jagiellonian University, Krakow, Poland The European Association of Percutaneous Cardiovascular Interventions
More informationRationale for Percutaneous Revascularization ESC 2011
Rationale for Percutaneous Revascularization Marie Claude Morice, Massy FR MD, FESC, FACC ESC 2011 Paris Villepinte - 27-31 August, 2011 Massy, France Potential conflicts of interest I have the following
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationBoston Scientific Corporation Drug-Eluting Stent Program
Boston Scientific Corporation Drug-Eluting Stent Program Copyright 2002 by Scimed Life Systems, Inc. All rights reserved. Program Overview λ λ λ λ λ World Wide Status Restenosis Paclitaxel Polymers Dose
More informationBiodegradable Polymer Drug- Eluting Stents Versus Durable Polymer Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention
Biodegradable Polymer Drug- Eluting Stents Versus Durable Polymer Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention A Pooled Analysis of Individual Patient Data from ISAR-TEST
More informationFOR IMMEDIATE RELEASE
FOR IMMEDIATE RELEASE Global Media Contacts: David Schull or Ian Stone Russo Partners +1 212-845-4271 +1 619-528-2220 david.schull@russopartnersllc.com ian.stone@russopartnersllc.com David Kujawa OrbusNeich
More informationThe titanium nitride oxide stent an alternative to DES. Adam de Belder MD FRCP Sussex Cardiac Centre BSUH on behalf of Hexacath
The titanium nitride oxide stent an alternative to DES Adam de Belder MD FRCP Sussex Cardiac Centre BSUH on behalf of Hexacath Advanced Angioplasty 2008 Declaration of interest I have received an honorarium
More informationThree-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.
Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G. Ellis MD Dean J. Kereiakes MD and Gregg W. Stone MD for the ABSORB
More informationDrug eluting balloon for bifurcation lesion: is it useful?
Welcome to the 8 th European Bifurcation Club 12-13 October 2012 - Barcelona Drug eluting balloon for bifurcation lesion: is it useful? Dr. Bruno Garcia Hospital Universitari Vall Hebrón Barcelona (Spain)
More informationBioresorbable Stents: Innovation or Bust?
Bioresorbable Stents: Innovation or Bust? Rajiv Jauhar, MD FACC, FSCAI Chief of Cardiology Director of Cardiac Cath Labs Northshore University Hospital San Diego July, 2016 Conflict of Interest Disclosure
More informationDrug eluting stents. Where are we now and what can we expect in 2003? Tony Gershlick Leicester
Drug eluting stents Where are we now and what can we expect in 2003? Tony Gershlick Leicester Trials Real World What we need i. Prevent restenosis cost effective Either : - Treat all at equivalent cost
More informationDevelopment Of DES Technology. HUO Yong,MD FACC Peking University First Hospital President-elect Chinese Society of Cardiology
Development Of DES Technology HUO Yong,MD FACC Peking University First Hospital President-elect Chinese Society of Cardiology Drug stents made in China Microport: Lepu: JW: Yinyi : Sinomed Yisheng Firebird
More informationA Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES.
A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES ISAR-TEST 2 Trial Robert A. Byrne, MB MRCPI Deutsches Herzzentrum and 1. Med.
More informationDRUG ELUTING STENTS. Cypher Versus Taxus: Are There Differences? Introduction. Methods SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C.
DRUG ELUTING STENTS Cypher Versus Taxus: Are There Differences? SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C. From the Cardiology Practice and Hospital, Munich, Germany Today, drug-eluting stents (DES) are
More informationStent Thrombosis: Patient, Procedural, and Stent Factors. Eugene Mc Fadden Cork, Ireland
Stent Thrombosis: Patient, Procedural, and Stent Factors Eugene Mc Fadden Cork, Ireland Definitions Early 1 yr TAXUS >6months CYPHER Incidence and Timing BMS Registry data
More informationConflict of interest :None. Meta-analysis. Zhangwei Chen, MD
Meta-analysis Addition of Cilostazol to Conventional Dual Antiplatelet Therapy Reduces the Risk of Cardiac Events and Restenosis after Drug-Eluting Stent Implantation Zhangwei Chen, MD Department of Cardiology,
More informationDrug Eluting Stents: Bifurcation and Left Main Approach
TCT Asia 2006 Drug Eluting Stents: Bifurcation and Left Main Approach Eberhard Grube MD FACC, FSCAI Heart Center,, Germany Stanford University, School of Medicine, CA, USA DES in High Risk Lesions TAXUS
More informationDrug Eluting Stents overhyped, overused and overpriced?
Advanced Angioplasty 2008 BCIS 23 rd Jan 2008 Drug Eluting Stents overhyped, overused and overpriced? William Wijns MD, PhD Cardiovascular Center Aalst http://www.cardio-aalst.be William.Wijns@village.uunet.be
More informationSide branch occlusion in 500 ABSORB BVS
Side branch occlusion in 500 ABSORB BVS Clinical implications and Solutions Robert-Jan van Geuns, MD, PhD Associate Professor,Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands On behalf
More informationResults of TROFI II Study. Patrick W. Serruys, MD, PhD. Imperial college, London, UK On behalf of the PI s and the TROFI II investigators
Comparison of the ABSORB TM Everolimus Eluting Bioresorbable Vascular Scaffold System With a Drug- Eluting Metal Stent (Xience TM ) in Acute ST-Elevation Myocardial Infarction: Results of TROFI II Study.
More informationWhat Stent to Use? JASVINDAR SINGH MD, FACC
What Stent to Use? JASVINDAR SINGH MD, FACC ASSOCIATE PROFESSOR OF MEDICINE WASHINGTON UNIVERSITY IN ST. LOUIS DIRECTOR, CARDIAC CATHETERIZATION LAB BARNES-JEWISH HOSPITAL What Stent to Use? Jasvindar
More informationIN-STENT RESTENOSIS. K.Boerlage-van Dijk CarVasZ 2014
IN-STENT RESTENOSIS K.Boerlage-van Dijk CarVasZ 2014 Definition ISR Angiographic: recurrent diameter stenosis >50% at the stent segment or edges (5-mm segments adjacent to stent) Mehran system morphological
More informationC. W. Hamm, B. Cremers, H. Moellmann, S. Möbius-Winkler, U. Zeymer, M. Vrolix, S. Schneider, U. Dietz, M. Böhm, B. Scheller
Paclitaxel-Eluting PTCA-Balloon in Combination with the Coroflex Blue Stent vs the Sirolimus Coated Cypher Stent in the Treatment of Advanced Coronary Artery Disease C. W. Hamm, B. Cremers, H. Moellmann,
More informationCoronary Stents: Past, Present and Future
Kardiologie Kardio Lunch 07.04.2016 Coronary Stents: Past, Present and Future Christoph Kaiser Universitätsspital Basel Rubin GS, The first balloon-expandable coronary stent, University of Queensland Press
More informationDr Li Shu Kin FRCP (Lond, Edin & Glasg) FACC FHKAM. COS (Medicine) Pamela Youde Nethersole Eastern Hospital
Dr Li Shu Kin FRCP (Lond, Edin & Glasg) FACC FHKAM COS (Medicine) Pamela Youde Nethersole Eastern Hospital Des 1904-1979 1929 Andreas Gruentzig 1939-1985 1 st case in Sept1977 Overtook CABG as the most
More informationLisette Okkels Jensen
A Randomized Trial Comparing a Polymer- Free Coronary Drug-Eluting Stent With an Ultra-Thin Strut Bioresorbable Polymer- Based Drug-Eluting Stent in an All-Comers Patient Population Lisette Okkels Jensen
More informationDrug Filled Stent Optical Coherence Tomography Results from RevElution Trial Stent Strut Coverage and Stent Apposition
Drug Filled Stent Optical Coherence Tomography Results from RevElution Trial Stent Strut Coverage and Stent Apposition Prof Martin Rothman on behalf of Dr. Stephen G. Worthley Alexandre Abizaid, Ajay J
More information2-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice
Journal of the American College of Cardiology Vol. 58, No. 1, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.023
More informationBIOFLOW by Orsiro stents
BIOFLOW by stents Byeong-Keuk Kim, MD, PhD Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine Key Benefits Clinically proven
More informationDavid E. Kandzari, MD Director, Interventional Cardiology Research Scripps Clinic La Jolla, California
38 RCTs 18,000 pts Identifying the Optimal Duration of DAPT Less is More, More or Less David E. Kandzari, MD Director, Interventional Cardiology Research Scripps Clinic La Jolla, California kandzari.david@scrippshealth.org
More informationTLR des Stents Actifs
TLR des Stents Actifs No Conflict of Interest Target Lesion Revascularization DES vs BMS Stettler C et al. Lancet 2007;370:937-48 N=18,023 58% 70% SES vs BMS: HR=0.30 (0.24-0.37), p
More informationDrug eluting balloons in CAD
Drug eluting balloons in CAD Ioannis Iakovou, MD, PhD Interventional Cardiology 1 st Cath Lab Onassis Cardiac Surgery Center Drug-Eluting Balloons (DEB) Technology and Applications 1. Special Features
More informationTRIAL UPDATE 1. ISAR TRIPLE SECURITY Trial. Dr Deven Patel Royal Free Hospital
TRIAL UPDATE 1 ISAR TRIPLE SECURITY Trial Dr Deven Patel Royal Free Hospital NO CONFLICT OF INTEREST TO DECLARE ISAR TRIPLE Comparison of 6 weeks vs 6 months Triple Therapy in patients on oral anticoagulation
More informationResults of TROFI II Study. Patrick W. Serruys, MD, PhD. Imperial college, London, UK On behalf of the PI s and the TROFI II investigators
Comparison of the ABSORB TM Everolimus Eluting Bioresorbable Vascular Scaffold System With a Drug- Eluting Metal Stent (Xience TM ) in Acute ST-Elevation Myocardial Infarction: Results of TROFI II Study.
More informationStent Thrombosis in Bifurcation Stenting
Summit TCT Asia Pacific 2009 Stent Thrombosis in Bifurcation Stenting Associate Professor Tan Huay Cheem MBBS, M Med(Int Med), MRCP, FRCP(UK), FAMS, FACC, FSCAI Director, National University Heart Centre,
More information1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES
1 Comparison of Ischemic and Bleeding Events After Drug- Eluting Stents or Bare Metal Stents in Subjects Receiving Dual Antiplatelet Therapy: Results from the Randomized Dual Antiplatelet Therapy (DAPT)
More informationmalapposition assessed by OCT
Stent t coverage and malapposition assessed by OCT Myeong-Ki Hong, M.D. Ph D Professor of Medicine Division of Cardiology, Severance Cardiovascular Hospital Yonsei University College of Medicine, Seoul,
More informationANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April The problem is exaggerated: Data from Real World Registries
ANGIOPLASY SUMMIT 007 TCT ASIA PACIFIC Seoul, Korea: 5-7 7 April 007 15 min Plenary Session: State-of of-the-art Lectures The problem is exaggerated: Data from Real World Registries Antonio Colombo Centro
More informationDauer der doppelten Plättchenhemmung nach AMI / Stent
Dauer der doppelten Plättchenhemmung nach AMI / Stent Kardio-Lunch 04.06.2014 Christoph Kaiser Universitätsspital Basel Christoph.kaiser@usb.ch DAPT after Stenting 257 patients with PCI & stent: ASS &
More informationLEADERS FREE ACS EN - Rev.01
C.K. Naber, P. Urban, P.J. Ong, M. Valdes-Chavarri, A. Abizaid, S.J. Pocock, F. Fabbiocchi, C. Dubois, S. Copt, S. Greene and M.C. Morice for the LEADERS FREE Investigators Presented by CK Naber EuroPCR
More information2-year outcome of the 3-arm BIO-RESORT randomized trial in all-comer patients treated with contemporary DES
2-year outcome of the 3-arm BIO-RESORT randomized trial in all-comer patients treated with contemporary DES Marlies M. Kok, MD Thoraxcentrum Twente, MST, Enschede, the Netherlands On behalf of the BIO-RESORT
More informationAffiliation/Financial Relationship
The Next ERA: COMBO Dual Therapy Stent The Unmet Need Roxana Mehran, MD Mount Sinai i School of Medicine i Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have
More informationBéla MERKELY MD, PhD, DSc, FESC. Stent thrombosis: patophysiology, predisposing factors, definition, classification, prevention and treatment
Semmelweis University Heart Center Budapest, Hungary Béla MERKELY MD, PhD, DSc, FESC Stent thrombosis: patophysiology, predisposing factors, definition, classification, prevention and treatment 10th Interventional
More information3-Year Clinical Outcomes in the Randomized SORT OUT III Superiority Trial Comparing Zotarolimus- and Sirolimus-Eluting Coronary Stents
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 5, NO. 8, 2012 2012 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcin.2012.04.008
More informationDr. Robert J. van Geuns. Thoraxcenter ErasmusMC Rotterdam On behalf of Dr. Jean Fajadet and Co-investigators
Complex coronary bifurcation lesions treated with the novel polymer-free dedicated bifurcation paclitaxel-eluting stent (Nile pax): clinical and angiographic results of the prospective, multicenter bipax
More informationThe present status of selfexpanding. for CLI: Why and when to use. Sean P Lyden MD Cleveland Clinic Cleveland, Ohio
The present status of selfexpanding and balloonexpandable tibial BMS and DES for CLI: Why and when to use Sean P Lyden MD Cleveland Clinic Cleveland, Ohio Disclosure Speaker name: Sean Lyden, MD I have
More information